Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Radiation Oncology
- Chemotherapy and Radiotherapy
- Paediatric Cancers
- Head and Neck Oncology
- Hormone Therapy
- Hematology
- Endometrial Cancer
- Surgical Oncology
Abstract
Citation: Clin Oncol. 2019;4(1):1647.DOI: 10.25107/2474-1663.1647
Does Statistical Decrease of Mortality Rates by a Factor of about 2.5 Suggest Revolutional Progress in Melanoma Treatment from Year 2009 to 2017?
Ernst-Peter Rührnschopf*
Imaging & Therapy Division, Healthcare Sector, Siemens Medical Systems, Erlangen, Germany
*Correspondance to: Ernst-Peter Rührnschopf
PDF Full Text Short Communication | Open Access
Abstract:
Comparison of mortality rates (for 5 years and 10 years, resp.), derived from the leading AJCC melanoma staging system references from 2009 and 2017, are showing an astounding decrease by a factor of about 2.5 (± 0.1) for different cutaneous melanoma stages, e.g. IIB, IIC, and IIIB, whereas the respective comparison between the former references from 2001 and 2009 amounts only to a factor of about 1.1 (± 0.05). The dramatic improvement in the short time from 2009 to 2017 suggests a revolutional progress in melanoma treatment, perhaps unsurpassed in the history of cancer.
Keywords:
Cite the Article:
Rührnschopf E-P. Does Statistical Decrease of Mortality Rates by a Factor of about 2.5 Suggest Revolutional Progress in Melanoma Treatment from Year 2009 to 2017?. Clin Oncol. 2019; 4: 1647 .
